Amneal Pharmaceuticals Financial Health
How is Amneal Pharmaceuticals's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AMRX's short term assets ($1.4B) exceed its short term liabilities ($818.0M).
Long Term Liabilities: AMRX's short term assets ($1.4B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: AMRX's net debt to equity ratio (1221.7%) is considered high.
Reducing Debt: AMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AMRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AMRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 23% per year.